Introduction: 708
Introduction
Inhibitory drug-drug interactions (DDIs) can result in significant increases in the area under the plasma concentration-time curve (AUC) of an object drug by reducing systemic clearance or increasing bioavailability. Due to potential adverse effects exacerbated by inhibitory DDIs, they are of serious concern in drug development. Consequently, the ability to reliably identify potential in vivo inhibitors and predict the magnitude of DDIs from in vitro data is necessary. should be used to determine relative exposures and that metabolites should also represent >10% of total drug related material.
Using retrospective data, it has been recognized that many P450 inhibitors possess circulating metabolites (Isoherranen et al., 2009) , and that inclusion of the metabolites in risk analysis can, in some cases, prevent false negative predictions (Yeung et al., 2011) . However, prospective studies aimed at understanding the importance of metabolites in DDI risk assessment are lacking, and the overall role of inhibitory metabolites in clinical DDIs and DDI predictions is still not well characterized. The relatively sparse data regarding inhibition potency of circulating metabolites (Yeung et al., 2011) has left the quantitative importance of metabolites in risk DMD/2013/051722 6 assessment controversial (Yu et al. 2012 ). In addition, very few studies have evaluated the importance of metabolites in irreversible interactions, despite the fact that most of clinically important mechanism-based inhibitors (MBI) possess circulating metabolites (VandenBrink and Isoherranen, 2010) . Hence more studies are needed to determine the role of circulating metabolites in reversible and irreversible P450 inhibition, and to evaluate the correlation between abundance of metabolites in circulation and their contribution to inhibitory DDIs.
Omeprazole (OMP), which is metabolized by CYP2C19 and CYP3A4 (Andersson et al., 1994 ) is also an in vivo inhibitor of these two enzymes (Yu et al., 2001; Angiolillo et al., 2011; Funck-Brentano et al., 1997; Soons et al., 1991) . OMP has been found to reversibly inhibit both CYP2C19 and CYP3A4 in vitro and recent investigations have shown that OMP is also an irreversible inhibitor of CYP2C19 (Ogilvie et al., 2011 Boulenc et al., 2012 . While in vivo DDIs with CYP2C19 substrates following OMP administration can largely be explained by CYP2C19 inactivation, the mechanisms of in vivo CYP3A4 interactions remain unexplained. It has been suggested that OMP metabolites may contribute to CYP2C19 inhibition (Ogilvie et al., 2011 ) but the metabolites have not been incorporated into DDI predictions and their circulating concentrations are not well characterized. In addition, it is possible that OMP metabolites are responsible for the in vivo CYP3A4 inhibition observed (Soons et al., 1991) . Since OMP is a weak-to-moderate inhibitor of CYP2C19 and CYP3A4 in vivo, inclusion of metabolites in DDI risk assessment may change the risk categorization significantly. Two of the omeprazole metabolites, 5-hydroxyomeprazole (OH-OMP) and omeprazole sulfone (OMP-S), are known to be present in plasma following omeprazole administration, and OMP-S shows elimination rate-limited kinetics in vivo (Regårdh et al., 1990) . While OMP-S inhibits both CYP2C19 and CYP3A4 reversibly in vitro, its contribution to in vivo CYP2C19 and CYP3A4 inhibition was This article has not been copyedited and formatted. The final version may differ from this version. Clinical Study: The study protocol was approved by the University of Washington Institutional
Review Board, and the study was registered at www.clinicaltrials.gov (NCT01361217). Plasma samples were obtained from the control day (no inhibitor) of the study. Nine subjects (5 men and 4 women) participating in a cocktail study received a validated cocktail (Ryu et al, 2007) (Ryu et al, 2007) . All participants were CYP3A5 non-expressers and CYP2C19
extensive metabolizers based on genotype analysis. Blood was collected at 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, and 12 hours following dosing, plasma separated from blood by centrifugation and stored at -80°C until analysis.
To establish the importance of conjugation reactions in the elimination of omeprazole metabolites an aliquot of each plasma sample was treated with either β -glucuronidase from
Escherichia coli or sulfatase from Aerobacter aerogenes. For β -glucuronidase treatment the enzyme was diluted in 100mM potassium phosphate buffer, pH 6.8 to a concentration of 500 units/mL. 50µL was then added to an equal volume of plasma and the samples were incubated in the dark at 37°C overnight. Deconjugation of dextrorphan glucuronide in blank plasma was used as a positive control. For sulfatase treatment, the enzyme was diluted in 100mM potassium phosphate buffer, pH 7.1 to a concentration of 1 unit/mL. 50µL was added to an equal volume of plasma and the samples were incubated in the dark at 37°C overnight. Deconjugation of 4-nitrocatechol sulfate dipotassium salt in plasma was used as a positive control.
Deconjugation to 4-nitrocatechol was determined by measuring the absorbance at 515 nM.
Negative control samples containing 50µL plasma and 50µL of the respective buffer were also incubated in the dark at 37°C overnight. 50µL of reaction mix was quenched in 100µL 1:3 acetonitrile:methanol containing 100nM omeprazole-d 3 internal standard. OMP, DM-OMP, OMP-S, C-OMP and OH-OMP were measured using LC/MS/MS as described below. The relative importance of the conjugates in plasma was determined by subtracting the concentrations of each analyte in control plasma from concentrations of the analytes in treated plasma. Analyst software version 1.4 (AB Sciex, Foster City, CA) was used for data analysis. The day-to-day coefficient of variation percentage for all analytes was <15%. The limit of quantification for 1'-hydroxymidazolam, OMP, OH-OMP, DM-OMP, OMP-S and C-OMP was 1nM and the limit of quantification for 4-hydroxymephenytoin was 50 nM.
Analysis of Omeprazole and Its Metabolites in

Determination of Protein Binding of Omeprazole and Its Metabolites and LogP
Calculations: OMP and its metabolites were added to 0.1 mg/mL HLM, 1.0 mg/mL HLM or blank plasma to yield a final concentration of 1 µM (plasma) or 10 µM (HLM) and protein binding was determined using ultracentrifugation as described previously (Templeton et al., 2008; Lutz and Isoherranen, 2012) . Samples were aliquoted into ultracentrifuge tubes (Beckman 343775) and incubated at 37°C for 90 min or spun at 435,000 g at 37°C for 90 minutes using a Sorval Discovery M150 SE ultracentrifuge with a Thermo Scientific S100-AT3
rotor ( 
Inactivation Experiments in HLMs and CYP3A4 supersomes to Determine K I and k inact
Values: Mechanism-based inhibition was evaluated using the dilution method previously described (Waley et al., 1985) . Incubations were performed in solutions containing 100 mM potassium phosphate buffer (KPi, pH 7.4). For CYP2C19 studies, HLM (1 mg/mL) were incubated at 37°C with OMP, DM-OMP or OMP-S (8 concentrations between 0.1 and 300 µM) and NADPH (1 mM). For CYP3A4 studies, HLM (1 mg/mL) were incubated at 37°C with OMP or DM-OMP (7 concentrations between 1 and 500 µM) and NADPH (1 mM). At four designated time points, 10 μL aliquots were diluted 10-fold into activity assays containing a saturating concentration of ( (Nishiya et al., 2009; Ogilvie et al., 2011; Fahmi et al., 2008 inhibition as described previously (Templeton et al., 2008) .
This article has not been copyedited and formatted. The final version may differ from this version. DM-OMP and C-OMP but not OMP-S, demonstrating a discrepancy between the two criteria.
In addition, DM-OMP and OMP-S AUCs are likely < 10% of total drug related material as OMP-S was 10% and DM-OMP was 1% of the total quantified drug related material in this study.
In the absence of radiolabelled data these values represent the upper limits of the abundance of the metabolites in relation to total drug related material. Since all four of the circulating metabolites were found to have exposures above 25% that of OMP when either the total or unbound AUCs were considered ( with the exception of DM-OMP, which has a higher ClogP than either OH-OMP or C-OMP but is less bound to plasma proteins (Table 1) . Fig. S1 and Table 2 ). All four metabolites (OH-OMP, DM-OMP, OMP-S and C-OMP) also inhibited CYP2C19 and CYP3A4 reversibly, with OMP-S being the most potent inhibitor based on the reversible IC 50 values (Supplemental Fig. S2 and Table 2 ). Interestingly, based on the IC 50 values, all of the metabolites except C-OMP were more potent CYP3A4
In vitro
inhibitors than OMP. OMP-S was a more potent CYP2C19 inhibitor than the other metabolites (Table 2 ). While C-OMP also inhibited CYP2C19 and CYP3A4, the IC 50 value for CYP2C19
could not be accurately determined due to lack of solubility of C-OMP (Supplemental Fig. S2 and Table 2 ).
When IC 50 -shift experiments were performed, a 10-fold NADPH-dependent shift for CYP2C19 and 1.5-fold IC 50 -shift for CYP3A4 were observed with OMP, suggesting irreversible inhibition of CYP2C19 and CYP3A4 by OMP ( Fig. 2 and Supplemental Table S1 ). Of the OMP metabolites, DM-OMP and OMP-S caused a ≥ 1.5-fold IC 50 -shift (7.3-and 2.1-fold respectively) with CYP2C19 and DM-OMP also caused an IC 50 -shift (2.0-fold) with CYP3A4 (Supplemental Table S1 ), suggesting that DM-OMP and OMP-S may contribute to the inactivation of CYP2C19, and DM-OMP may contribute to CYP3A4 inactivation. No significant IC 50 -shift (< 1.5-fold shift) was observed with either OH-OMP or C-OMP in the presence of NADPH with CYP2C19 or CYP3A4, suggesting that OH-OMP and C-OMP do not inactivate CYP2C19 or CYP3A4 (Supplemental Fig. S3 and Supplemental Table S1 ).
To characterize the irreversible inhibition of CYP2C19 and CYP3A4 by OMP and its metabolites, the K I and k inact values were determined for OMP and those metabolites that showed (Table 2) . Of the three CYP2C19 inactivators, OMP appeared to be most efficient based on the k inact /K I ratios. Time-and concentration-dependent inactivation of CYP3A4 was also observed with OMP and DM-OMP, as predicted from the IC 50 -shift experiments (Fig. 4) . OMP and DM-OMP were less potent inactivators of CYP3A4 than CYP2C19 based on the fact that their K I values were 7-10 fold higher towards CYP3A4. Yet, the k inact value for OMP was similar towards both CYP3A4 and CYP2C19 while DM-OMP had a slightly higher (4.3-fold) k inact value towards CYP3A4 than towards CYP2C19 (Table 2 ). In contrast to the rank order of inhibition efficiency between the compounds with CYP2C19, DM-OMP was a more efficient irreversible inhibitor of CYP3A4 than OMP based on the 3-fold higher k inact /K I ratio.
To assess whether CYP2C19-mediated formation of the DM-OMP is required for the irreversible inhibition of CYP3A4 by OMP in HLMs, inactivation of CYP3A4 by OMP was further evaluated using CYP3A4 supersomes. As shown in Fig. 4 , irreversible inhibition of CYP3A4 by OMP was observed in the absence of CYP2C19 and OMP had a higher K I (157 μM) and k inact (0.054 min -1 ) towards CYP3A4 in supersomes when compared to HLMs. The inactivation efficiency in supersomes was slightly lower than in HLMs, based on the k inact /K I ratio.
The ClogP's of OMP and its metabolites were compared to the IC 50 values and k inact /K I ratios to assess whether lipophilicity was predictive of the inhibition potency (Tables 1 and 2 For reversible CYP2C19 inhibition, the contribution of the metabolites was predicted to be up to 47% of the total interaction risk ( Fig. 5 and Supplemental Fig. S4 ). However, the inhibition of CYP2C19 following OMP administration was determined to be mainly due to the inactivation of CYP2C19 by OMP and/or its metabolites. Hence, the metabolites were predicted to contribute up to 33% of CYP2C19 inhibition based on unbound concentrations. In contrast, with CYP3A4, based on unbound concentrations, metabolites contribute 88 % of the total hepatic CYP3A4 inhibition risk when reversible inhibition is considered, and up to 63% when irreversible inhibition is considered (Fig. 5 , and Table 3 inhibitor itraconazole, the minor metabolite N-desalkyl-itraconazole is predicted to have similar importance in in vivo DDIs as the major metabolite hydroxy-itraconazole (Templeton et al., 2008) . Similarly with the CYP2D6 inhibitor bupropion, erythrobupropion is predicted to have similar role in in vivo DDIs as hydroxybupropion despite its 10-fold lower circulating concentrations (Yeung et al., 2011) . To partially address this apparent discrepancy between metabolite exposure and importance in DDIs, consideration of the logP of metabolites was recently recommended for decision-trees regarding testing of specific metabolites for inhibition (Yu et al., 2012) . In addition, it was suggested that for drugs that have structural alerts for MBI, such as alkyamines and epoxides, metabolites should be tested regardless of their exposure (Yu et al., 2012) . However, many compounds, such as omeprazole, are MBIs but do not have obvious structural alerts to trigger DDI evaluation. The aim of this study was to determine, using OMP as an example, whether circulating total or unbound metabolite concentrations could be used to guide in vitro metabolite testing strategy, and whether metabolite contribution will aid in predicting in vivo DDIs.
In this study circulating metabolites of OMP were characterized. As a conservative approach, quantified metabolites were evaluated in vitro if they met any of the criteria for circulating metabolites described by the FDA or EMA. However, DM-OMP only meets the criteria of >25% of the parent using unbound concentrations and it is <10% of total drug related material. As such it is unclear if testing of this quantitatively minor metabolite would be considered necessary. Furthermore, the EMA guidance may not require testing of any of these metabolites. Overall the analysis of in vivo AUC m /AUC p ratios determined for OMP and its metabolites demonstrates the discrepancies and ambiguity of decision making for metabolite testing. When metabolite evaluation is based solely based on metabolite exposure, DM-OMP is the metabolite that would likely be omitted. However, this was the only metabolite that is expected to contribute to in vivo DDIs with CYP2C19 and CYP3A4 and evaluation of OH-OMP, OMP-S and C-OMP could be considered unnecessary. Hence, it is important to further develop cutoffs for metabolite testing and ensure that the metabolites that are important in DDIs are tested.
Prioritization of metabolite testing based on the lipophilicity of the metabolites has been suggested so that metabolites that are less lipophilic than the parent drug should circulate at concentrations >100% of the parent to warrant testing for reversible inhibition (Yu et al., 2012) .
In the present study, all of the metabolites were estimated to be less lipophilic than OMP, except for OMP-S. As such, if metabolite lipophilicity is considered, OMP-S would warrant attention.
However, its contribution to the overall DDI risk was predicted to be minimal (5-8% when unbound C max is used) so testing of OMP-S could be considered unnecessary. With consideration of lipophilicity, DM-OMP would not be studied unless it was flagged for MBI. , 1997) , the AUC of diazepam by 25% (Ishizaki et al 1995) and decreases the formation of the active metabolite of clopidogrel (Angiolillo et al., 2011) . OMP also appears to inhibit CYP3A4
in vivo based on a 25% increase in nifedipine AUC (Soons et al., 1991) and 90% increase in carbamazepine AUC (Dixit et al., 2001) (Obach et al., 2007; Fujioka et al., 2012) . Hence, with OMP, the conservative approach of using total C max values would likely provide adequate data to trigger in vivo studies without consideration of metabolites.
To our knowledge, irreversible inhibition of CYP3A4 by OMP and the inactivation kinetics of CYP2C19 and CYP3A4 by OMP metabolites have not been previously characterized. The inactivation kinetics of CYP2C19 by OMP has been reported and the DDI between clopidogrel and OMP has been predicted using OMP data alone (Ogilvie et al., 2011; Boulenc et al., 2012) .
This article has not been copyedited and formatted. The final version may differ from this version. In addition, OMP-S was previously shown to cause an IC 50 -shift in vitro with CYP2C19, and the inactivation of CYP2C19 by OMP was proposed to involve DM-OMP (Ogilvie et al., 2011 ).
Our studies demonstrate that DM-OMP is an inactivator of CYP2C19, and it is possible that the proposed mechanisms in which a reactive quinoneimine is formed after 5'-O-demethylation by CYP2C19 is responsible for CYP2C19 inactivation (Ogilvie et al., 2011) . However, if quinoneimine formation from DM-OMP is required for CYP2C19 inactivation, it is surprising that the k inact value was the highest for OMP in comparison to OMP-S and DM-OMP. It is unclear how inactivation proceeds from OMP-S, which has not been shown to undergo O-demethylation. Further studies are required to determine the mechanism of CYP2C19 inactivation by OMP. The reactive quinoneimine formation by CYP3A4 may be responsible for CYP3A4 inactivation as the inactivation rate was faster from DM-OMP than OMP and OMP-S did not result in CYP3A4 inactivation. While the DM-OMP formation is generally believed to be by CYP2C19 (Andersson and Weidolf, 2008) , the data in CYP3A4 supersomes shows that CYP3A4 inactivation does not require CYP2C19. This suggests that either CYP3A4 forms sufficient quantities of DM-OMP that is not released from CYP3A4 active site and results in CYP3A4 inactivation, or that the quinoneimine is not responsible for CYP3A4 inactivation. The qualitative differences between CYP2C19 and CYP3A4 inactivation by OMP and its metabolites are of interest as they demonstrate that P450 inactivation mechanisms and relative metabolite contributions cannot be easily generalized and extrapolated. The data also show that metabolites Further work is required to develop the kinetic theory for multiple inactivators according to the theory provided for alkylamines (Zhang et al., 2009a (Zhang et al., , 2009b ).
In conclusion, the results of this study show that identification of MBIs during drug development is critically important for DDI risk assessment. Based on the obtained data, DM-OMP is responsible for the majority of hepatic CYP3A4 inhibition while metabolites are responsible for <50% of the overall CYP2C19 inhibition. While metabolites may contribute to in vivo DDIs, their importance may not be related to their relative abundance in plasma. As such, better models need to be developed to prioritize metabolite testing in DDI assessment.
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